PRMA Insights: The Roadmap to Pricing and Reimbursement Success

The type 2 diabetes report delivers

Use this report to gain an understanding of the following issues in the pricing and reimbursement of type 2 diabetes in the major markets:

• An overview of glucose control in type 2 diabetes, with a focus on the key issues shaping the market access landscape.
  
• A comprehensive review of glucose control products, regulatory indications, key supporting data packages and positioning in clinical guidelines.
  
• How payors have critically evaluated the data packages for existing type 2 diabetes products.
  
• An in-depth critical review of over 125 pricing and reimbursement and HTA assessments in type 2 diabetes in the major markets.
  
• The price existing products have achieved and their reimbursement status in each country.
  
• The value propositions and arguments manufacturers have submitted most recently and the success of these strategies.
  
• A review of the treatments by country and the implications when seeking an indication for diabetes.
  
• The implications surrounding the choice of comparators and endpoints included in clinical trials.
  
• The key learnings and market access insights for developing a new glucose control product in type 2 diabetes.
  
• A review of the epidemiology and burden of type 2 diabetes with insights into evidence gaps and the impact on your health outcomes strategy.
  
• A review of the existing instruments used to measure health-related quality of life (HRQoL) in type 2 diabetes, opportunities for the inclusion of HRQoL data in your label and how this could differentiate your product and impact pricing and reimbursement. 
  
  

Find out more about the type 2 diabetes report:

The report delivers         Scope of the report        Authors of the report